Holen Sie sich die Stockscreener-App
1.15
0.00%
0.00
Handel nachbörslich:
1.17
0.02
+1.74%
Schlusskurs vom Vortag:
$1.15
Offen:
$1.14
24-Stunden-Volumen:
338.01K
Relative Volume:
0.68
Marktkapitalisierung:
$52.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.9829
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
-1.71%
1M Leistung:
-29.01%
6M Leistung:
-31.55%
1J Leistung:
-70.51%
1-Tages-Spanne:
$1.12
$1.1796
1-Wochen-Bereich:
$1.02
$1.2795
52-Wochen-Spanne:
$0.8505
$4.32
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.15 | 53.48M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology Corporation Stock Analysis and ForecastDynamic capital growth - jammulinksnews.com
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - MSN
What drives PDS Biotechnology Corporation stock priceFree Stock Movement Tracking - jammulinksnews.com
What analysts say about PDS Biotechnology Corporation stockMarket-beating performance - jammulinksnews.com
How PDS Biotechnology Corporation stock performs during market volatilityHigh Yield Stock Selection - Newser
Is PDS Biotechnology Corporation a good long term investmentSuperior capital gains - printweek.in
Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser
What makes PDS Biotechnology Corporation stock price move sharplyFree Access to Investment Community - Newser
PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com Nigeria
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance
PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener
PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria
PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia
PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times
PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan
PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology holds a conference call - TipRanks
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World
PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada
PDS Biotech expands equity incentive plan - Investing.com
PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK
PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times
PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):